IGF-DES (also known as IGF-1 DES or des(1-3)IGF-1) is a synthetic, truncated version of the naturally occurring Insulin-like Growth Factor 1 (IGF-1). It is primarily used in laboratory research for its enhanced potency compared to standard IGF-1.
Key Characteristics
- Molecular Structure: It is formed by removing the first three amino acids (Gly-Pro-Glu) from the N-terminus of the IGF-1 molecule. This leaves a 67-amino acid chain instead of the standard 70.
- Reduced Binding Protein Affinity: The primary reason for its high potency is its inability to bind effectively to IGF-binding proteins (IGFBPs). Because it isn’t “trapped” by these proteins, it is more bioavailable and active at the receptor level.
- Enhanced Potency: Studies indicate it is approximately 10 times more potent than native IGF-1 in stimulating cell growth and muscle tissue modeling.
- Short Half-Life: It has a very short biological half-life of roughly 20–30 minutes. Due to this, it is often associated with localized effects at the site of administration rather than systemic growth.
Common Applications
- Research: Used in experiments focusing on cell proliferation, muscle recovery, and regenerative processes.
- Bodybuilding (Off-label): In some athletic circles, it is used for “site-specific” muscle growth or to target “lagging” muscle groups, though it is not approved for human consumption or medical use in this capacity.
- Potential Medical Avenues: Research has explored its use for treating muscle wasting in chronic kidney disease and inflammatory bowel diseases, though clinical trials in humans have not been fully evaluated.
Safety and Legal Status
- Regulatory Status: IGF-DES is not FDA-approved for human use and is strictly sold for research purposes only.
- Side Effects: Similar to IGF-1, potential risks include hypoglycemia, joint pain, muscle pain, and, in extreme cases, edema or facial drooping (Bell’s palsy). High levels are also a marker for conditions like acromegaly.
Reviews
There are no reviews yet.